Scholar Rock is a clinical-stage biopharmaceutical company creating a robust pipeline of therapeutics with the potential to transform the lives of patients suffering from serious diseases, including neuromuscular disorders, cancer, fibrosis, and anemia. Our proprietary platform is rooted in our structural biology insights into the activation of latent growth factor precursors and drives the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By exploiting structural differences in the precursor, or latent form of growth factors, Scholar Rock intends to avoid the historical dose-limiting safety challenges associated with inhibiting the mature form of growth factors for therapeutic effect.
Our lead product candidate, SRK-015, is a highly specific inhibitor of myostatin activation currently being evaluated in a Phase 2 proof-of-concept trial for the treatment of patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA). SRK-015 has received Orphan Drug Designation in both the US and EU.
Our second product candidate, SRK-181, is a potent and highly selective inhibitor of latent TGFβ1 activation. A Phase 1 proof-of-concept trial was initiated in April 2020 in patients with solid tumors. We believe SRK-181 has the potential to meaningfully increase the number of patients who can benefit from checkpoint inhibitor therapy by overcoming primary resistance to anti-PD-(L)1 antibodies.
Summary of Position:
We are seeking a highly motivated computational biologist to join us in developing best-in-class antibody-based therapeutics across multiple disease areas. This position affords an opportunity to build and lead a robust data science platform, interfacing with research and clinical development teams and with external vendors. Consequently, he/she will significantly impact interdisciplinary programs across Scholar Rock’s R&D pipeline. The successful candidate will effectively translate biological questions into data science approaches supporting clinical biomarker identification and validation; drug discovery, preclinical efficacy, and mechanism of action studies; and new target validation efforts.